Relugolix

瑞卢戈利

Report date: 2026/04/13 20:02:18
NME

Base Information

Drug NameRelugolix
Drug Alias NameRelugolixum瑞卢戈利ReluminaORGOVYXP76B05O5V6 (UNII code) +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGonadotropin-releasing hormone receptor antagonists
TargetsGonadotropin-releasing hormone receptor
Therapy Area/IndicationsContraceptionUterine FibroidsHormone-Sensitive Prostate Neoplasms +[12] 
Global Approved IndicationsProstatic NeoplasmsLeiomyoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2019/01/08
Country/TerritoryCzechiaBelgiumBulgaria +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTakeda Pharmaceutical Co LtdRoivant Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityGedeon RichterSumitomo Pharma Switzerland GmbH +[22] 
Inactive CompaniesDana-Farber Cancer InstituteMyovant Sciences Ireland LtdYale University +[9] 
Active IndicationsContraceptionUterine FibroidsHormone-Sensitive Prostate Neoplasms +[10] 
Inactive IndicationsMenorrhagiaUterine Neoplasms

Other Information

ATC CodeL01XX
Related LinksWikipediaDrugBankKEGG